MRNA

#489
Moderna, Inc. Common Stock
53.57
+4.77%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
53.57
53.59
Jahresspanne
22.29
55.19
Tagesänderung
+4.77%
Monatliche Änderung
+17.79%
6 month change
+113.94%
Jahresänderung
+73.99%
Vorheriger Schlusskurs
51.13
Open
53.59
Bid
Ask
Low
53.57
High
53.59
Volumen
356
Open full chart

Financials

Overview Finanzbericht Statistics Dividends
Quarterly Annual
  • Market Capitalization 20.84 B
  • Employee 5 800
  • Founded N/A
  • CEO Stéphane Bancel
  • Website www.modernatx.com
  • Headquarter Delaware, United States
  • FIGI BBG003PHHZT1
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-4.06
Price to sales ratio
5.9
Dividends per share
—
Dividend yield %
—

Moderna Inc

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.

Nachrichten